Virtual Booth

The MedDNA Portable Detector is a mobile DNA-based diagnostic innovation developed to address the growing needs of modern medicine within the digital health era. Conventional diagnostic methods are often constrained by long waiting times for results, high testing costs, and heavy reliance on centralized laboratory facilities, which are commonly located in urban areas. This creates a critical gap in healthcare accessibility, particularly for patients in rural communities, where the lack of timely diagnosis frequently results in delayed treatment, greater disease complications, and increased financial burdens. The primary objective of the MedDNA project is to provide a compact and user-friendly diagnostic tool that can deliver fast, accurate, and reliable results in diverse healthcare settings. The device is specifically designed to detect genetic disorders such as thalassemia and cystic fibrosis, infectious diseases including HIV, hepatitis, and tuberculosis, as well as early-stage cancers. With only a small blood sample, results can be obtained within 15 to 30 minutes, offering a significant improvement over conventional methods that typically require days or even weeks. In terms of methodology, MedDNA integrates several advanced technologies to achieve high sensitivity and precision. These include CRISPR-Cas (Cas12a/Cas13a) systems for DNA and RNA detection, a microfluidics platform that processes samples through disposable cartridges, mini PCR modules for DNA amplification, and graphene or quantum dot-based nanochip biosensors that generate highly accurate electrical signals. The results are processed by a microcontroller such as Arduino Nano or Raspberry Pi Pico and displayed on an LCD screen with LED indicators for user convenience. The novelty of MedDNA lies in its hybrid integration of molecular biology, nanotechnology, and microelectronics within a portable device approximately the size of a power bank. Unlike conventional laboratory-based diagnostics, this innovation offers speed, affordability, and accessibility while maintaining high accuracy. Its applicability extends beyond urban hospitals to small clinics, district health centers, and rural communities, making it a versatile solution for early disease detection and management. Commercially, MedDNA has significant market potential. The projected selling price of RM1,500–2,000 per unit, combined with disposable cartridges priced between RM20 and RM40 per test, makes it substantially more affordable than conventional genetic laboratory tests, which can cost up to RM1,500 per test. The impact of this innovation is far-reaching, as it enhances early treatment effectiveness, improves patient safety, and reduces the overall strain on healthcare systems. Furthermore, MedDNA aligns with the United Nations Sustainable Development Goals, particularly SDG 3 on Good Health and Well-Being and SDG 9 on Industry, Innovation, and Infrastructure. With strong potential for both national and international commercialization, MedDNA stands as a transformative tool that bridges the gap between modern technology and equitable healthcare access.